Estrogen receptor antagonists are anti-cryptococcal agents that directly bind EF hand proteins and synergize with fluconazole in vivo

mBio

Volumn 5, Issue 1, 2014, Pages

  Butts, Arielle ^a   Koselny, Kristy ^b   Chabrier Roselló, Yeissa ^c   Semighini, Camile P ^c   Brown, Jessica C S ^d   Wang, Xuying ^c   Annadurai, Sivakumar ^e   DiDone, Louis ^b   Tabroff, Julie ^a   Childers Jr , Wayne E ^e   Abou Gharbia, Magid ^e   Wellington, Melanie ^b   Cardenas, Maria E ^c   Madhani, Hiten D ^d   Heitman, Joseph ^c   Krysan, Damian J ^b  

^a UNIVERSITY OF ROCHESTER   (United States)

^b UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^c DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e TEMPLE UNIVERSITY SCHOOL OF PHARMACY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,1,2 TRIPHENYLETHYLENE DERIVATIVE; AMPHOTERICIN B; ANTIFUNGAL AGENT; CALCINEURIN; CALMODULIN; CALMODULIN LIKE PROTEIN 1; CLOMIFENE; EF HAND PROTEIN; ESTROGEN RECEPTOR ANTAGONIST; FLUCONAZOLE; FUNGAL PROTEIN; IDOXIFENE; METHYLENEIDOXIFENE; TAMOXIFEN; TOREMIFENE; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR CRZ1; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICRYPTOCOCCAL ACTIVITY; ANTIFUNGAL ACTIVITY; ARTICLE; CELL NUCLEUS; CONTROLLED STUDY; CRYPTOCOCCOSIS; CRYPTOCOCCUS NEOFORMANS; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG MEGADOSE; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG TARGETING; DRUG TISSUE LEVEL; ENZYME ACTIVATION; ENZYME SUBSTRATE; FUNGAL CELL; FUNGUS GROWTH; FUNGUS MUTANT; GENETIC SCREENING; GROWTH INHIBITION; IN VITRO STUDY; IN VIVO STUDY; MACROPHAGE; MALE; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN LOCALIZATION; PROTEIN PURIFICATION;

ANTIFUNGAL AGENTS; CRYPTOCOCCUS NEOFORMANS; DRUG SYNERGISM; EF HAND MOTIFS; FLUCONAZOLE; FUNGAL PROTEINS; PROTEIN BINDING; SELECTIVE ESTROGEN RECEPTOR MODULATORS; TAMOXIFEN; TOREMIFENE;

EID: 84903369179     PISSN: 21612129     EISSN: 21507511     Source Type: Journal    
DOI: 10.1128/mBio.00765-13     Document Type: Article

References (53)

1. Park BJ, Wannemuehler KA, Marston BJ, Govender N, Pappas PG, Chiller TM. 2009. Estimation of the current global burden of cryptococcal meningitis among persons living with HIV/AIDS. AIDS 23:525-530. http://dx.doi.org/10.1097/QAD.0b013e328322ffac.
2. Chayakulkeeree M, Perfect JR. 2006. Cryptococcosis. Infect. Dis. Clin. North Am. 20:507-544. http://dx.doi.org/10.1016/j.idc.2006.07.001.
3. Perfect JR. 2012. The triple threat of cryptococcosis: it's the body site, the strain and/or the host. mBio 3:e100165-12. http://dx.doi.org/10.1128/ mBio.00165-12.
4. Perfect JR, Dismukes WE, Dromer F, Goldman DL, Graybill JR, Hamill RJ, Harrison TS, Larsen RA, Lortholary O, Nguyen MH, Pappas PG, Powderly WG, Singh N, Sobel JD, Sorrell TC. 2010. Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the Infectious Diseases Society of America. Clin. Infect. Dis. 50:291-322. http://dx.doi.org/10.1086/649858.
5. Day JN, Chau TT, Wolbers M, Mai PP, Dung NT, Mai NH, Phu NH, Nghia HD, Phong ND, Thai CQ, Thaile H, Chuong LV, Sinh DX, Duong VA, Hoang TN, Diep PT, Campbell JI, Sieu TP, Baker SG, Chau NV, Hien TT, Lalloo DG, Farrar JJ. 2013. Combination therapy for cryptococcal meningitis. N. Engl. J. Med. 368:1291-1302. http:// dx.doi.org/10.1056/NEJMoa1110404.
6. Sloan DJ, Dedicoat MJ, Lalloo DG. 2009. Treatment of cryptococcal meningitis in resource-limited settings. Curr. Opin. Infect. Dis. 22: 455-463. http://dx.doi.org/10.1097/QCO.0b013e32832fa214.
7. Bicanic T, Muzoora C, Brouwer AE, Meintjes G, Longley N, Taseera K, Rebe K, Loyse A, Jarvis J, Bekker LG, Wood R, Limmathurotsakul D, Chierakul W, Stepniewska K, White NJ, Jaffar S, Harrison TS. 2009. Independent association of clearance of infection and clinical outcome of HIV-associated cryptococcal meningitis: analysis of combined cohort of 262 patients. Clin. Infect. Dis. 49:702-709. http://dx.doi.org/10.1086/ 604716.
8. Butts A, Krysan DJ. 2012. Antifungal drug discovery: something old and something new. PLoS Pathog. 8:e1002870. http://dx.doi.org/10.1371/ journal.ppat.1002870.
9. Wermuth CG. 2004. Selective optimization of side activities: another way for drug discovery. J. Med. Chem. 47:1303-1314. http://dx.doi.org/ 10.1021/jm030480f.
10. Bisson WH. 2012. Drug repurposing in chemical genomics: can we learn from the past to improve the future? Curr. Top. Med. Chem. 12: 1867-1868. http://dx.doi.org/10.2174/156802612804547399.
11. Butts A, DiDone L, Koselny K, Baxter BK, Chabrier-Rosello Y, Wellington M, Krysan DJ. 2013. A repurposing approach identifies off-patent drugs with fungicidal cryptococcal activity, a common structural chemotype, and pharmacological properties relevant to the treatment of cryptococcosis. Eukaryot. Cell 12:278-287. http://dx.doi.org/10.1128/ EC.00314-12.
12. Wiseman H, Cannon M, Arnstein HR. 1989. Observation and significance of growth inhibition of Saccharomyces cerevisiae (A224A) by the anti-oestrogen drug tamoxifen. Biochem. Soc. Trans. 17:1038-1039.
13. Dolan K, Montgomery S, Buchheit B, DiDone L, Wellington M, Krysan DJ. 2009. The antifungal activity of tamoxifen: in vitro, in vivo, and mechanistic characterization. Antimicrob. Agents Chemother. 53:3337-3346. http://dx.doi.org/10.1128/AAC.01564-08.
14. Spitzer M, Griffiths E, Blakely KM, Wildenhain J, Ejim L, Rossi L, De Pascale G, Curak J, Brown E, Tyers M, Wright GD. 2011. Cross-species discovery of syncretic drug combinations that potentiate the antifungal fluconazole. Mol. Syst. Biol. 7:499. http://dx.doi.org/10.1038/ msb.2011.31.
15. Morello KC, Wurz GT, DeGregorio MW. 2003. Pharmacokinetics of selective estrogen receptor modulators. Clin. Pharmacokinet. 42:361-372. http://dx.doi.org/10.2165/00003088-200342040-00004.
16. Zhang L, Yu J, Pan H, Hu P, Hao Y, Cai W, Zhu H, Yu AD, Xie X, Ma D, Yuan J. 2007. Small molecule regulators of autophagy identified by an image-based high-throughput screen. Proc. Natl. Acad. Sci. U. S. A. 104: 19023-19028. http://dx.doi.org/10.1073/pnas.0709695104.
17. Voelz K, May RC. 2010. Cryptococcal interactions with the host immune system. Eukaryot. Cell 9:835-846. http://dx.doi.org/10.1128/EC.00039-10.
18. Herrmann JL, Dubois N, Fourgeaud M, Basset D, Lagrange PH. 1994. Synergic activity of amphotericin-B and gamma interferon against intracellular Cryptococcus neoformans in macrophages. J. Antimicrob. Chemother. 34:1051-1058. http://dx.doi.org/10.1093/jac/34.6.1051.
19. National Committee for Clinical Laboratory Standards. 2002. Reference method for broth dilution antifungal susceptibility testing of yeasts. Approved standard M27-MA2. National Committee for Clinical Laboratory Standards, Wayne, PA.
20. Mukherjee PK, Sheehan DJ, Hitchcock CA, Ghannoum MA. 2005. Combination treatment of invasive fungal infections. Clin. Microbiol. Rev. 18:163-194. http://dx.doi.org/10.1128/CMR.18.1.163-194.2005.
21. Del Poeta M, Cruz MC, Cardenas ME, Perfect JR, Heitman J. 2000. Synergistic antifungal activities of bafilomycin A(1), fluconazole, and the pneumocandin MK0991/caspofungin acetate (L-743,873) with calcineurin inhibitors FK506 and L-685,818 against Cryptococcus neoformans. Antimicrob. Agents Chemother. 44:739-746. http://dx.doi.org/10.1128/ AAC.44.3.739-746.2000.
22. Lara PN, Jr, Gandara DR, Wurz GT, Lau D, Uhrich M, Turrell C, Raschko J, Edelman MJ, Synold T, Doroshow J, Muggia F, Perez EA, DeGregorio M. 1998. High-dose toremifene as a cisplatin modulator in metastatic non-small cell lung cancer: targeted plasma levels are achievable clinically. Cancer Chemother. Pharmacol. 42:504-508. http:// dx.doi.org/10.1007/s002800050852.
23. Decaudin D, Etienne MC, De Cremoux P, Maciorowski Z, Vantelon JM, Voog E, Urien S, Tran-Perennou C, Renée N, Vielh P, Némati F, Pouillart P. 2004. Multicenter phase II feasibility trial of high dose tamoxifen in patients with refractory or relapsed multiple myeloma. J. Natl. Cancer Inst. 96:636-637. http://dx.doi.org/10.1093/jnci/djh108.
24. Alanio A, Desnos-Ollivier M, Dromer F. 2011. Dynamics of Cryptococcus neoformans-macrophage interactions reveal that fungal background influences outcome during cryptococcal meningoencephalitis in humans. mBio 2:e00158-e00159. http://dx.doi.org/10.1128/mBio.00158-11.
25. Harrison TS, Griffin GE, Levitz SM. 2000. Conditional lethality of the diprotic weak bases chloroquine and quinacrine against Cryptococcus neoformans. J. Infect. Dis. 182:283-289. http://dx.doi.org/10.1086/315649.
26. Miguel DC, Yodoyama-Yasunaka JKU, Andreioli WK, Moratara RA, Uliana SRB. 2007. Tamoxifen is effective against Leishmania and induces a rapid alkalization of the parasiophorous vacuoles harbouring Leishmania (Leishmania) amazonensis amastigotes. J. Antimicrob. Ther. 60: 526-534. http://dx.doi.org/10.1093/jac/dkm219.
27. Robinson SP, Langan-Fahey SM, Johnson DA, Jordan VC. 1991. Metabolites, pharmacodynamics, and pharmacokinetics of tamoxifen in rats and mice compared to the breast cancer patient. Drug Metab. Dispos. 19:36-43.
28. Iusuf D, Teunissen SF, Wagenaar E, Rosing H, Beijnen JH, Schinkel AH. 2011. P-glycoprotein (ABCB1) transports the primary active tamoxifen metabolites endoxifen and 4-hydroxytamoxifen and restricts their brain penetration. J. Pharmacol. Exp. Ther. 337:710-717. http:// dx.doi.org/10.1124/jpet.110.178301.
29. Lien EA, Wester K, Lønning PE, Solheim E, Ueland PM. 1991. Distribution of tamoxifen and metabolites into brain tissue and brain metastases in breast cancer patients. Br. J. Cancer 63:641-645. http://dx.doi.org/ 10.1038/bjc.1991.147.
30. Kuroiwa S, Koyama M, Watanabe N, Ekimoto H, Ohnishi Y, Saito M, Maruo K, Inaba M, Tashiro T, Yamori T, et al. 1993. Antitumor activity of a new antiestrogenic drug, toremifene (NK622) against human breast cancer xenografts in nude mice. Gan To Kagaku Ryoho 20:617-623.
31. Parsons AB, Lopez A, Givoni TE, Williams DE, Gray CA, Porter J, Chua G, Sopko R, Brost RL, Ho CH, Wang J, Ketela T, Brenner C, Brill JA, Fernandez GE, Lorenz TC, Payne GS, Ishihara S, Ohya Y, Andrews B, Hughes TR, Frey BJ, Graham TR, Andersen RJ, Boone C. 2006. Exploring the mode-of-action of bioactive compounds by chemical-genetic profiling in yeast. Cell 126:611-625. http://dx.doi.org/10.1016/ j.cell.2006.06.040.
32. Lopes MC, Vale MG, Carvalho AP. 1990. Ca2(+)-dependent binding of tamoxifen to calmodulin isolated from bovine brain. Cancer Res. 50: 2753-2758.
33. Senistenra G, Chau I, Vedad M. 2011. Thermal denaturation assays in chemical biology. Assay Drug Dev. Technol. 10:128-136.
34. Kraus PR, Heitman J. 2003. Coping with stress: calmodulin and calcineurin in model and pathogenic fungi. Biochem. Biophys. Res. Commun. 311:1151-1157. http://dx.doi.org/10.1016/S0006-291X(03)01528-6.
35. Kozubowski L, Thompson JW, Cardenas ME, Moseley MA, Heitman J. 2011. Association of calcineurin with the COPI protein Sec28 and the COPII protein Sec13 revealed by quantitative proteomics. PLoS One 6:e25280. http://dx.doi.org/10.1371/journal.pone.0025280.
36. Cyert MS. 2001. Genetic analysis of calmodulin and its targets in S. cerevisiae. Annu. Rev. Genet. 35:647-672. http://dx.doi.org/10.1146/ annurev.genet.35.102401.091302.
37. Peters C, Mayer A. 1998. Ca2+/calmodulin signals completion of docking and triggers a late step of vacuole fusion. Nature 396:575-580. http:// dx.doi.org/10.1038/25133.
38. Kraus PR, Nichols CB, Heitman J. 2005. Calcium-and calcineurinindependent roles for calmodulin in Cryptococcus neoformans morphogenesis and high-temperature growth. Eukaryot. Cell 4:1079-1087. http:// dx.doi.org/10.1128/EC.4.6.1079-1087.2005.
39. Lev S, Desmarini D, Chayakulkeeree M, Sorrell TC, Djordjevic JT. 2012. The Crz1/Sp1 transcription factor of Cryptococcus neoformans is activated by calcineurin and regulates cell wall integrity. PLoS One 7:e51403. http://dx.doi.org/10.1371/journal.pone.0051403.
40. Stathopoulos AM, Cyert MS. 1997. Calcineurin acts through the CRZ1/ TCN1-encoded transcription factor to regulate gene expression in yeast. Genes Dev. 11:3432-3444. http://dx.doi.org/10.1101/gad.11.24.3432.
41. Schenone M, Dančík V, Wagner BK, Clemons PA. 2013. Target identification and mechanism of action in chemical biology and drug discovery. Nat. Chem. Biol. 9:232-240. http://dx.doi.org/10.1038/nchembio.1199.
42. Greier BM, Wiech H, Schiebel E. 1996. Binding of centrins and yeast calmodulin to synthetic peptides corresponding to binding sites in the spindle pole body components Kar1p and Spc110p. J. Biol. Chem. 45: 28366-28374.
43. Gulino A, Barrera G, Vacca A, Farina A, Ferretti C, Screpanti I, Dianzani MU, Frati L. 1986. Calmodulin antagonism and growthinhibiting activity of triphenylethylene antiestrogens in MCF-7 human breast cancer cells. Cancer Res. 46:6274-6278.
44. Rowlands MG, Budworth J, Jarman M, Hardcastle IR, McGague R, Gescher A. 1995. Comparison between protein kinase C inhibition and antagonism of calmodulin by tamoxifen analogues. Biochem. Pharmacol. 50:723-726. http://dx.doi.org/10.1016/0006-2952(95)00186-4.
45. Hardcastle IR, Rowlands MG, Grimshaw RM, Houghton J, Jarman M. 1996. Homologs of idoxifene: variations of estrogen receptor binding and calmodulin antagonism with chain length. J. Med. Chem. 39:999-1004. http://dx.doi.org/10.1021/jm9505472.
46. Gupta SS, Ton VK, Beaudry V, Rulli S, Cunningham K, Rao R. 2003. Antifungal activity of amiodarone is mediated by disruption of calcium homeostasis. J. Biol. Chem. 278:28831-28839. http://dx.doi.org/10.1074/ jbc.M303300200.
47. Edlind T, Smith L, Henry K, Katiyar S, Nickels J. 2002. Antifungal activity in Saccharomyces cerevisiae is modulated by calcium signaling. Mol. Microbiol. 46:257-268. http://dx.doi.org/10.1046/j.1365-2958.2002.03165.x.
48. Benaim B, Garcia CR. 2011. Targeting calcium homeostasis as a therapy of Chagas' disease and leishmanisis-a review. Trop. Biomed. 28: 471-481.
49. Liu OW, Chun CD, Chow ED, Chen C, Madhani HD, Noble SM. 2008. Systematic genetic analysis of virulence in the human fungal pathogen Cryptococcus neoformans. Cell 135:174-188. http://dx.doi.org/10.1016/ j.cell.2008.07.046.
50. Burke DJ, Dawson D, Stearns T. 2000. Methods in yeast genetics. CSHL Press, Woodbury, NY.
51. Dittmar JC, Reid RJ, Rothstein R. 2010. ScreenMill: A freely available software suite for growth measurement, analysis and visualization of highthroughput screen data. BMC Bioinformatics 11:353-363. http:// dx.doi.org/10.1186/1471-2105-11-353.
52. Collins SR, Schuldiner M, Krogan NJ, Weissman JS. 2006. A strategy for extracting and analyzing large-scale quantitative epistatic interaction data. Genome Biol. 7:R63. http://dx.doi.org/10.1186/gb-2006-7-7-r63.
53. Bolstad BM, Irizarry RA, Astrand M, Speed TP. 2003. A comparison of normalization methods for high density oligonucleotide array data based on variance and bias. Bioinformatics 19:185-193. http://dx.doi.org/ 10.1093/bioinformatics/19.2.185.